EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive‐stage small cell lung cancer (ES‐SCLC): ECOG‐ACRIN EA5161

Ticiana A Leal iD, Yating Wang, Afshin Dowlati iD, Christopher H Chay, Yuanbin Chen, Amit R Mohindra, Mohammad Razaq, Harish G Ajuja, Jijun Liu, David M King, Christopher J Sumey, Suresh S Ramalingam iD

Cancer · 15.06.2025 · 131 (12)

DOI: 10.1002/cncr.35938 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 17.06.2025. Verfasst von Ticiana A Leal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Winship Cancer Institute of Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Nivolumab showed durable responses in patients with small cell lung cancer (SCLC). A randomized phase II study investigating nivolumab plus cisplatin/carboplatin and etoposide (PE) versus PE for patients with untreated extensive‐stage (ES) SCLC was conducted.

Methods

Patients with untreated ES‐SCLC, Eastern Cooperative Oncology Group performance status 0‐1, were randomized 1:1 to nivolumab 360 mg intravenously (IV) plus cisplatin 75 mg/m 2 or carboplatin area under the curve 5 on day 1 and etoposide 100 mg/m 2 (PE) on days 1–3 every 21 days for four cycles followed by nivolumab 240 mg intravenously (arm A) every 2 weeks on a 6‐week cycle for up to 2 years or PE alone (Arm B) for 4 cycles followed by observation. The primary endpoint was progression‐free survival (PFS). The primary comparison of PFS used a logrank test stratified on the randomization stratification factors with a one‐sided type I error rate of 10%. Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.

Results

Overall, 160 patients were enrolled; 144 patients were treated and constituted the primary analysis. The median PFS was 5.5 months (95% confidence interval [CI], 4.3–5.9 months) on arm A, and 4.9 months (95% CI, 4.5–5.7 months) on arm B (hazard ratio, 0.78; p = .083). The estimated median OS was 11.2 months (95% CI, 8.8–14.2 months) on arm A and 8.1 months (95% CI, 7.2–9.6 months) on arm B (hazard ratio, 0.71; p = .059).

Conclusion

The combination of PE and nivolumab improves both PFS and OS for patients with ES‐SCLC. No new safety signals were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaNivolumabAntineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsHumansEtoposideFemaleCarboplatinMaleCisplatinMiddle AgedAgedAdultProgression-Free SurvivalNeoplasm Staging

Stichwörter der Autor:innen

carboplatinetoposideimmunotherapysmall cell lung cancer

Substanzen

EtoposideCarboplatinNivolumabCisplatin

Autor:innen und Institutionen

  • Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  • Dana Farber Cancer Institute ECOG-ACRIN Biostatistics Center, Boston, Massachusetts, USA.
  • Case Western Reserve University, Cleveland, Ohio, USA.
  • Messino Cancer Centers, Asheville, North Carolina, USA.
  • Cancer Research Consortium of West Michigan NCORP, Grand Rapids, Michigan, USA.
  • Henry Ford Cancer Institute, Detroit, Michigan, US.

ORCID-Profile: Ticiana A Leal, Afshin Dowlati, Suresh S Ramalingam

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Leal, T. A., Wang, Y., Dowlati, A., Chay, C. H., Chen, Y., Mohindra, A. R., Razaq, M., Ajuja, H. G., Liu, J., King, D. M., Sumey, C. J., & Ramalingam, S. S. (2025). Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive‐stage small cell lung cancer (ES‐SCLC): ECOG‐ACRIN EA5161. Cancer, 131(12). https://doi.org/10.1002/cncr.35938

Vancouver

Leal TA, Wang Y, Dowlati A, Chay CH, Chen Y, Mohindra AR, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive‐stage small cell lung cancer (ES‐SCLC): ECOG‐ACRIN EA5161. Cancer. 2025;131(12). doi:10.1002/cncr.35938

BibTeX
@article{Leal2025,
  author = {Leal, Ticiana A and Wang, Yating and Dowlati, Afshin and Chay, Christopher H and Chen, Yuanbin and Mohindra, Amit R and Razaq, Mohammad and Ajuja, Harish G and Liu, Jijun and King, David M and Sumey, Christopher J and Ramalingam, Suresh S},
  title = {Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive‐stage small cell lung cancer (ES‐SCLC): ECOG‐ACRIN EA5161},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {12},
  doi = {10.1002/cncr.35938}
}
Kostenlos starten →